Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Envoy Medical (COCH) Amortization of Deferred Charges (2024 - 2025)

Envoy Medical's Amortization of Deferred Charges history spans 2 years, with the latest figure at $4000.0 for Q4 2025.

On a quarterly basis, Amortization of Deferred Charges fell 98.96% to $4000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a N/A change, with the full-year FY2025 number at $1.6 million, up 94.85% from a year prior.
Amortization of Deferred Charges hit $4000.0 in Q4 2025 for Envoy Medical, down from $468000.0 in the prior quarter.
Over the last five years, Amortization of Deferred Charges for COCH hit a ceiling of $623000.0 in Q2 2025 and a floor of $4000.0 in Q4 2025.